Development of isourea-based covalent GPX4 inhibitors and structure–activity relationship analysis in ferroptosis induction
4 affiliations
- 1Fudan University Shanghai 200433 China
- 2School of Life Sciences, Westlake University Hangzhou 310024 Zhejiang China
- 3Keen Therapeutics, Co., Ltd. Suzhou 215000 China
- 4Department of Chemistry, School of Science, Westlake University Hangzhou 310024 Zhejiang China
Abstract
Ferroptosis holds significant promise for cancer therapeutics. While inhibition of glutathione peroxidase 4 (GPX4), a central intrinsic defense against ferroptosis, is sufficient to induce this process in cancer cells, the scarcity of bioavailable GPX4 inhibitors has hindered both mechanistic studies in vivo and therapeutic exploration. Furthermore, the absence of a well-defined ligand-binding pocket and the high intrinsic reactivity of traditional covalent chemotypes complicate inhibitor optimization. Inspired by the SN2-like geometry of the oxidative step in GPX4 catalysis, we developed a heterobenzylic isourea as a tunable leaving group for covalent GPX4 inhibitor design. Systematic variation of the isourea substituent, heteroaromatic scaffold, conformational rigidity, distal side chain, and stereochemistry established comprehensive structure–activity relationships. A key intermediate, compound 100, confirmed on-target ferroptotic activity by inducing lipid peroxidation and liproxstatin-1-rescuable cytotoxicity across cancer cell lines, while an alkyne-tagged analogue enabled cellular GPX4 target enrichment. Further optimization delivered two complementary, orally bioavailable leads. Compound 418 is a potent cellular probe (IC50 = 7.7 nM), whereas compound 380 combines the lowest systemic clearance among the series in mice together with dose-proportional oral exposure. Oral administration of compound 380 suppresses tumor growth in both 786-O and MDA-MB-468 xenografts. [1H,15N]-HSQC measurements support enhanced GPX4–ligand interaction under dodecylphosphocholine (DPC) membrane-mimetic conditions. Beyond defining the medicinal-chemistry characteristics of this isourea compound series, our work establishes non-retained leaving-group engineering as a strategy for developing covalent GPX4 inhibitors with tunable cellular and pharmacokinetic properties.
Related
- SGLT2 inhibitors attenuate diabetic kidney disease by suppressing YAP dependent ferroptosis
- Salvage surgery for advanced non-small cell lung cancer after induction therapy with selective RET inhibitors: safety and feasibility.
- The relationship between 5α-reductase inhibitors and the presence of following open angle glaucoma: a TriNetX cohort study.
- Relationship between overall survival and progression-free survival with 18 F-FDG PET/CT metabolic parameters in metastatic breast cancer patients treated with CDK 4/6 inhibitors
- Relationship between subjective socioeconomic status and depression in Chinese rural adolescents: positive youth development as a moderator
BibTeX
@article{lu2026development,
title = {{Development of isourea-based covalent GPX4 inhibitors and structure–activity relationship analysis in ferroptosis induction}},
author = {Yang Lu and Zijian Pan and Lijie Bai and Senhao Xiao and Xin Gu and Jiayu Li and Weihua Shi and Xiaoxiao Zhang and Shi’en Liu and Chong Lu and Zhou Zhou and Rongsheng Ma and Yingqiang Xu and Qianli Tan and Hong’e Qu and Die Hu and Bolin Liu and Lili Fan and Hongqing Yao and Zhiwen Chen and Weiwei Fan and Qiwen Qian and Jun Cao and Wu Hou and Qiu Li and Caiyi Wei and Wenqin Zeng and Nathchar Naowarojna and Jun Yu and Yikai Wang and Yilong Zou},
journal = {RSC Chemical Biology},
year = {2026},
month = nov,
doi = {10.1039/d6cb00321d},
url = {https://doi.org/10.1039/d6cb00321d},
note = {CC BY-NC 3.0},
}
RIS
TY - JOUR
TI - Development of isourea-based covalent GPX4 inhibitors and structure–activity relationship analysis in ferroptosis induction
AU - Yang Lu
AU - Zijian Pan
AU - Lijie Bai
AU - Senhao Xiao
AU - Xin Gu
AU - Jiayu Li
AU - Weihua Shi
AU - Xiaoxiao Zhang
AU - Shi’en Liu
AU - Chong Lu
AU - Zhou Zhou
AU - Rongsheng Ma
AU - Yingqiang Xu
AU - Qianli Tan
AU - Hong’e Qu
AU - Die Hu
AU - Bolin Liu
AU - Lili Fan
AU - Hongqing Yao
AU - Zhiwen Chen
AU - Weiwei Fan
AU - Qiwen Qian
AU - Jun Cao
AU - Wu Hou
AU - Qiu Li
AU - Caiyi Wei
AU - Wenqin Zeng
AU - Nathchar Naowarojna
AU - Jun Yu
AU - Yikai Wang
AU - Yilong Zou
PY - 2026
DA - 2026/11/12
JO - RSC Chemical Biology
DO - 10.1039/d6cb00321d
UR - https://doi.org/10.1039/d6cb00321d
AB - Ferroptosis holds significant promise for cancer therapeutics. While inhibition of glutathione peroxidase 4 (GPX4), a central intrinsic defense against ferroptosis, is sufficient to induce this process in cancer cells, the scarcity of bioavailable GPX4 inhibitors has hindered both mechanistic studies in vivo and therapeutic exploration. Furthermore, the absence of a well-defined ligand-binding pocket and the high intrinsic reactivity of traditional covalent chemotypes complicate inhibitor optimization. Inspired by the SN2-like geometry of the oxidative step in GPX4 catalysis, we developed a heterobenzylic isourea as a tunable leaving group for covalent GPX4 inhibitor design. Systematic variation of the isourea substituent, heteroaromatic scaffold, conformational rigidity, distal side chain, and stereochemistry established comprehensive structure–activity relationships. A key intermediate, compound 100, confirmed on-target ferroptotic activity by inducing lipid peroxidation and liproxstatin-1-rescuable cytotoxicity across cancer cell lines, while an alkyne-tagged analogue enabled cellular GPX4 target enrichment. Further optimization delivered two complementary, orally bioavailable leads. Compound 418 is a potent cellular probe (IC50 = 7.7 nM), whereas compound 380 combines the lowest systemic clearance among the series in mice together with dose-proportional oral exposure. Oral administration of compound 380 suppresses tumor growth in both 786-O and MDA-MB-468 xenografts. [1H,15N]-HSQC measurements support enhanced GPX4–ligand interaction under dodecylphosphocholine (DPC) membrane-mimetic conditions. Beyond defining the medicinal-chemistry characteristics of this isourea compound series, our work establishes non-retained leaving-group engineering as a strategy for developing covalent GPX4 inhibitors with tunable cellular and pharmacokinetic properties.
SN - 2633-0679
ER -